Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium
Esther N. Dekker·Laura R Prakasha·Alice C Wei·Marc G Besselink·Bas Groot Koerkamp·Laura R Prakash·Eileen M O’Reilly·Ching-Wei D. Tzeng·Eva M M Verkolf·Alessandro Paniccia·Amer H Zureikat·Roeland F de Wilde·David van Klaveren·Matthew H. G. Katz
Survival at restaging after neoadjuvant chemotherapy of patients with localized PDAC is determined by eight patient, tumor and treatment response characteristics. A web-based calculator can inform clinicians and patients about individualized prognosis and guide further management.